Toxicokinetic modeling and its applications in chemical risk assessment.

In recent years physiologically based pharmacokinetic (PBPK) modeling has found frequent application in risk assessments where PBPK models serve as important adjuncts to studies on modes of action of xenobiotics. In this regard, studies on mode of action provide insight into both the sites/mechanisms of action and the form of the xenobiotic associated with toxic responses. Validated PBPK models permit calculation of tissue doses of xenobiotics and metabolites for a variety of conditions, i.e. at low-doses, in different animal species, and in different members of a human population. In this manner, these PBPK models support the low-dose and interspecies extrapolations that are important components of current risk assessment methodologies. PBPK models are sometimes referred to as physiological toxicokinetic (PT) models to emphasize their application with compounds causing toxic responses. Pharmacokinetic (PK) modeling in general has a rich history. Data-based PK compartmental models were developed in the 1930's when only primitive tools were available for solving sets of differential equations. These models were expanded in the 1960's and 1970's to accommodate new observations on dose-dependent elimination and flow-limited metabolism. The application of clearance concepts brought many new insights about the disposition of drugs in the body. In the 1970's PBPK/PT models were developed to evaluate metabolism of volatile compounds of occupational importance, and, for the first time, dose-dependent processes in toxicology were included in PBPK models in order to assess the conditions under which saturation of metabolic and elimination processes lead to non-linear dose response relationships. In the 1980's insights from chemical engineers and occupational toxicology were combined to develop PBPK/PT models to support risk assessment with methylene chloride and other solvents. The 1990's witnessed explosive growth in risk assessment applications of PBPK/PT models and in applying sensitivity and variability methods to evaluate model performance. Some of the compounds examined in detail include butadiene, styrene, glycol ethers, dioxins and organic esters/aids. This paper outlines the history of PBPK/PT modeling, emphasizes more recent applications of PBPK/TK models in health risk assessment, and discusses the risk assessment perspective provided by modern uses of these modeling approaches.

[1]  J. Young,et al.  PHARMACOKINETICS OF INHALED OR INTRAPERITONEALLY ADMINISTERED STYRENE IN RATS , 1979 .

[2]  J. Blancato,et al.  Incorporation of biological information in cancer risk assessment: Example — Vinyl chloride , 1989, Cell Biology and Toxicology.

[3]  J. Young,et al.  Pharmacokinetics of inhaled styrene in human volunteers. , 1980, Toxicology and applied pharmacology.

[4]  Yu. Pogoreltsev,et al.  The Application , 2020, How to Succeed in the Academic Clinical Interview.

[5]  C J Portier,et al.  Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. , 1992, Cancer research.

[6]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[7]  M E Andersen,et al.  Physiological modelling of organic compounds. , 1991, The Annals of occupational hygiene.

[8]  H. B. Matthews,et al.  Using Structural Information to Create Physiologically Based Pharmacokinetic Models for All Polychlorinated Biphenyls: I. Tissue:Blood Partition Coefficients , 1997 .

[9]  R. Dedrick,et al.  Cisplatin pharmacokinetics: applications of a physiological model. , 1988, Toxicology letters.

[10]  A. Holmes,et al.  Mortality experience of workers exposed to vinyl chloride monomer in the manufacture of polyvinyl chloride in Great Britain. , 1977, British journal of industrial medicine.

[11]  Melvin E. Andersen,et al.  Gas Uptake Inhalation Techniques and the Rates of Metabolism of Chloromethanes, Chloroethanes, and Chloroethylenes in the Rat , 1990 .

[12]  D J Paustenbach,et al.  Pharmacokinetics of [125I]-2-iodo-3,7,8-trichlorodibenzo-p-dioxin in mice: analysis with a physiological modeling approach. , 1990, Toxicology and applied pharmacology.

[13]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[14]  J. Young,et al.  Pharmacokinetics of 1,4-dioxane in humans. , 1977, Journal of toxicology and environmental health.

[15]  Douglas Shepard Riggs The Mathematical Approach To Physiological Problems: A Critical Primer , 1970 .

[16]  J. Morris,et al.  A physiologically based pharmacokinetic model for nasal uptake and metabolism of nonreactive vapors. , 1993, Toxicology and applied pharmacology.

[17]  Kannan Krishnan,et al.  Molecular Structure-Based Prediction of the Partition Coefficients of Organic Chemicals for Physiological Pharmacokinetic Models , 1996 .

[18]  H. Haggard THE ABSORPTION, DISTRIBUTION, AND ELIMINATION OF ETHYL ETHER III. THE RELATION OF THE CONCENTRATION OF ETHER, OR ANY SIMILAR VOLATILE SUBSTANCE, IN THE CENTRAL NERVOUS SYSTEM TO THE CONCENTRATION IN THE ARTERIAL BLOOD, AND THE BUFFER ACTION OF THE BODY , 1924 .

[19]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[20]  G. Levy,et al.  Pharmacokinetics of salicylate elimination in man. , 1965, Journal of pharmaceutical sciences.

[21]  F. Lundquist,et al.  The kinetics of alcohol elimination in man. , 2009, Acta pharmacologica et toxicologica.

[22]  A. Guarino,et al.  Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: experimental observations and distributed modeling. , 1982, Journal of pharmaceutical sciences.

[23]  C J Portier,et al.  Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism. , 1998, Toxicology and applied pharmacology.

[24]  M. McKenna,et al.  The pharmacokinetics of [14C]vinylidene chloride in rats following inhalation exposure. , 1978, Toxicology and applied pharmacology.

[25]  E. Kitagawa On mortality. , 1977, Demography.

[26]  H J Clewell,et al.  A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.

[27]  M E Andersen,et al.  Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. , 1996, Toxicology and applied pharmacology.

[28]  P. Allen,et al.  Physiological model for the pharmacokinetics of methyl mercury in the growing rat. , 1993, Toxicology and applied pharmacology.

[29]  M. W. Sauerhoff,et al.  Dose-dependent pharmacokinetic profile of silvex following intravenous administration in rats. , 1977, Journal of toxicology and environmental health.

[30]  Franklin G. King,et al.  Physiological Model for the Pharmacokinetics , 1985 .

[31]  M. Andersen,et al.  Physiologically based modeling of vinyl acetate uptake, metabolism, and intracellular pH changes in the rat nasal cavity. , 1997, Toxicology and applied pharmacology.

[32]  F. Lundquist,et al.  The influence of fructose on the kinetics of alcohol elimination in man. , 2009, Acta pharmacologica et toxicologica.

[33]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[34]  F E Yates,et al.  Good manners in good modeling: mathematical models and computer simulations of physiological systems. , 1978, The American journal of physiology.

[35]  M. McKenna,et al.  The pharmacokinetics of inhaled methylene chloride in rats. , 1982, Toxicology and applied pharmacology.

[36]  J. Young,et al.  The dose-dependent fate of 1,4-dioxane in rats. , 1978, Journal of Environmental Pathology And Toxicology.

[37]  G. Blau,et al.  The dose-dependent pharmacokinetic profile of 2,4,5-trichlorophenoxy acetic acid following intravenous administration to rats. , 1976, Toxicology and applied pharmacology.

[38]  S. Kety The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.

[39]  M. McKenna,et al.  Metabolism and pharmacokinetic profile of vinylidene chloride in rats following oral administration. , 1978, Toxicology and applied pharmacology.

[40]  H W Leung,et al.  Development and utilization of physiologically based pharmacokinetic models for toxicological applications. , 1991, Journal of toxicology and environmental health.

[41]  M E Andersen,et al.  Modeling the tissue solubilities and metabolic rate constant (Vmax) of halogenated methanes, ethanes, and ethylenes. , 1988, Toxicology letters.

[42]  W W MAPLESON,et al.  An electric analogue for uptake and exchange of inert gases and other agents. , 1963, Journal of applied physiology.

[43]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[44]  Chlorinated Paraffins,et al.  Canadian Environmental Protection Act Priority Substances List Assessment Report , 1995 .

[45]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[46]  H J Clewell,et al.  A physiologically based simulation approach for determining metabolic constants from gas uptake data. , 1986, Toxicology and applied pharmacology.

[47]  A. Andersen,et al.  A collaborative study of cancer incidence and mortality among vinyl chloride workers. , 1991, Scandinavian journal of work, environment & health.

[48]  M. Gibaldi,et al.  Pharmacokinetics, Second Edition , 1982 .

[49]  荒井保明 Pharmacokinetics , 1993 .

[50]  C F Hendriksen,et al.  Lifespan oral toxicity study of vinyl chloride in rats. , 1981, Food and cosmetics toxicology.

[51]  A. Hayes Principles and methods of toxicology , 1982 .

[52]  D. Farrar,et al.  Assessing the health risks following environmental exposure to hexachlorobutadiene. , 2003, Toxicology letters.

[53]  D. Edelson,et al.  Computer Simulation in Chemical Kinetics , 1981, Science.

[54]  H J Clewell,et al.  Improving toxicology testing protocols using computer simulations. , 1989, Toxicology letters.

[55]  Marc Montminy,et al.  A Transcriptional Switch Mediated by Cofactor Methylation , 2001, Science.

[56]  K. Krishnan,et al.  Molecular Structure-Based Prediction of the Toxicokinetics of Inhaled Vapors in Humans , 1999 .

[57]  D. Smith,et al.  A mortality study of vinyl chloride monomer workers employed in the United Kingdom in 1940-1974. , 1988, Scandinavian journal of work, environment & health.

[58]  D J Paustenbach,et al.  A physiologically based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice. , 1988, Toxicology letters.

[59]  A Sato,et al.  A vial-equilibration method to evaluate the drug-metabolizing enzyme activity for volatile hydrocarbons. , 1979, Toxicology and applied pharmacology.

[60]  M E Andersen,et al.  Dosimetric adjustment factors for methyl methacrylate derived from a steady-state analysis of a physiologically based clearance-extraction model. , 1999, Inhalation toxicology.

[61]  C. Maltoni,et al.  Carcinogenicity bioassays of vinyl chloride monomer: a model of risk assessment on an experimental basis. , 1981, Environmental health perspectives.

[62]  H. Bolt,et al.  Pharmacokinetics of Halogenated Ethylenes , 1978 .

[63]  E. Glover,et al.  [125I]2-iodo-3,7,8-trichlorodibenzo-p-dioxin-binding species in mouse liver induced by agonists for the Ah receptor: characterization and identification. , 1989, Molecular pharmacology.

[64]  D. H. Tedeschi,et al.  Importance of fundamental principles in drug evaluation , 1968 .

[65]  P. Watanabe,et al.  Resolution of dose-response toxicity data for chemicals requiring metabolic activation: example--vinyl chloride. , 1978, Toxicology and applied pharmacology.

[66]  H. Bolt,et al.  Pharmacokinetics of halogenated ethylenes in rats , 1978, Archives of Toxicology.

[67]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[68]  C B Frederick,et al.  Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: an example with acrylic acid. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[69]  P. Duarte A mechanistic model of the effects of light and temperature on algal primary productivity , 1995 .

[70]  E. Glover,et al.  Stimulation of in vivo hepatic uptake and in vitro hepatic binding of [125I]2-lodo-3,7,8-trichlorodibenzo-p-dioxin by the administration of agonist for the Ah receptor. , 1989, Molecular pharmacology.

[71]  H J Clewell,et al.  Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.

[72]  M E Andersen,et al.  Regional hepatic CYP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. , 1997, Toxicology and applied pharmacology.

[73]  P. Watanabe,et al.  Fate of [14C]vinyl chloride following inhalation exposure in rats. , 1976, Toxicology and applied pharmacology.

[74]  D. Gardner Toxicology of the Lung , 2005 .

[75]  E Dybing,et al.  [Drinking water and health]. , 1994, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[76]  A Sato,et al.  Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. , 1979, British journal of industrial medicine.

[77]  C B Frederick,et al.  Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways. , 1998, Toxicology and applied pharmacology.

[78]  V. Fiserova-Bergerova,et al.  Mathematical modeling of inhalation exposure , 1976 .

[79]  H. Matthews,et al.  Distribution and excretion of 2,2',4,4',5,5'-hexabromobiphenyl in rats and man: pharmacokinetic model predictions. , 1980, Toxicology and applied pharmacology.

[80]  Rory B. Conolly,et al.  Physiologically Based Pharmacokinetic Model of the Metabolism of Trichloroethylene by an Isolated Ventilated Perfused Lung , 1990 .

[81]  J. Landes Application of a J-Q Model for Fracture in the Ductile-Brittle Transition , 1997 .

[82]  G. Clark,et al.  A mechanistic model of effects of dioxin on gene expression in the rat liver. , 1993, Toxicology and applied pharmacology.

[83]  D J Paustenbach,et al.  A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. , 1990, Toxicology and applied pharmacology.

[84]  V. Fiserova-Bergerova,et al.  Predictable "individual differences" in uptake and excretion of gases and lipid soluble vapours simulation study. , 1980, British journal of industrial medicine.

[85]  H. Haggard,et al.  THE ABSORPTION, DISTRIBUTION, AND ELIMINATION OF ETHYL ETHER II. ANALYSIS OF THE MECHANISM OF ABSORPTION AND ELIMINATION OF SUCH A GAS OR VAPOR AS ETHYL ETHER , 1924 .

[86]  Richard D. Thomas Drinking Water and Health , 1986 .

[87]  C. Maltoni,et al.  Experimental research on vinyl chloride carcinogenesis , 1984 .

[88]  Robert L. Dedrick,et al.  Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[89]  M E Andersen,et al.  A biologically based risk assessment for vinyl acetate-induced cancer and noncancer inhalation toxicity. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[90]  C. Allegra,et al.  The kinetics of methotrexate polyglutamation in human breast cancer cells. , 1987, Archives of biochemistry and biophysics.

[91]  M. Andersen,et al.  Kinetic characterization of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes , 1998, Archives of Toxicology.

[92]  M. Andersen,et al.  Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.

[93]  Y. Sugiyama,et al.  Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. , 1997, The Journal of pharmacology and experimental therapeutics.

[94]  C DeRosa,et al.  Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. , 1997, Toxicology and applied pharmacology.

[95]  R. J. Lutz,et al.  A review of the applications of physiologically based pharmacokinetic modeling , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[96]  R. Coulombe,et al.  Pharmacokinetics in Risk Assessment , 1996 .

[97]  M E Andersen,et al.  Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[98]  D. Holaday,et al.  Uptake and clearance of inhalation anesthetics in man. , 1979, Drug metabolism reviews.